15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $53M | -$11M | 62.5% | -12.2% | -$9M | $38M | $32M |
| 2024 | $48M | -$23M | 61.0% | -39.2% | -$19M | $38M | $32M |
| 2023 | $52M | -$19M | 64.5% | -33.0% | -$6M | $33M | $44M |
| 2022 | $45M | -$23M | 65.4% | -52.9% | -$21M | $0 | $10M |
| 2021 | $49M | -$15M | 69.3% | -29.8% | -$11M | — | $31M |
| 2020 | $28M | -$12M | 63.2% | -72.5% | -$17M | — | $42M |
| 2019 | $28M | -$20M | 67.6% | -73.9% | -$20M | — | $59M |
| 2018 | $17M | $63M | 65.2% | -86.0% | -$21M | $0 | $17M |
| 2017 | $10M | -$5M | 68.0% | -135.7% | -$4M | $3M | $10M |
| 2016 | — | -$12M | — | — | -$3M | $3M | $14M |
| 2015 | — | -$5M | — | — | -$6M | $140000 | $12M |
| 2014 | — | -$17M | — | — | -$1M | — | $6M |
| 2013 | — | -$4M | — | — | -$3M | $3M | $8M |
| 2012 | — | $617000 | — | — | -$588000 | — | $4M |
| 2011 | — | $109000 | — | — | $1M | — | $5M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $12M | -$2M | 63.5% | -7.3% | -$632000 | $38M | $31M |
| Dec '25 | $19M | -$1M | 62.6% | 0.1% | -$3M | $38M | $32M |
| Sep '25 | $13M | -$2M | 64.4% | -6.5% | -$4M | $38M | $25M |
| Jun '25 | $11M | -$4M | 62.3% | -22.6% | -$1M | $38M | $29M |
| Mar '25 | $9M | -$4M | 60.1% | -32.4% | -$757000 | $38M | $31M |
| Dec '24 | $14M | -$5M | 63.0% | -21.4% | -$3M | $38M | $32M |
| Sep '24 | $11M | -$5M | 60.5% | -31.6% | -$5M | $38M | $28M |
| Jun '24 | $12M | -$7M | 61.7% | -45.7% | -$5M | $34M | $33M |
| Mar '24 | $10M | -$8M | 58.1% | -64.6% | -$6M | $33M | $37M |
| Dec '23 | $15M | -$10M | 60.9% | -39.4% | -$2M | $33M | $44M |
| Sep '23 | $12M | -$5M | 66.6% | -38.7% | $4M | $9M | $22M |
| Jun '23 | $14M | -$994000 | 68.4% | -9.1% | -$5M | $9M | $18M |
| Mar '23 | $12M | -$3M | 62.4% | -46.2% | -$2M | $9M | $16M |
| Dec '22 | $13M | -$6M | 65.3% | -47.3% | -$5M | $0 | $10M |
| Sep '22 | $9M | -$6M | 63.2% | -63.4% | -$6M | — | $15M |
| Jun '22 | $10M | -$5M | 67.2% | -58.1% | -$6M | — | $20M |
| Mar '22 | $12M | -$6M | 65.8% | -47.0% | -$5M | — | $26M |
| Dec '21 | $17M | -$2M | 72.2% | -10.1% | -$118000 | — | $31M |
| Sep '21 | $12M | -$4M | 68.1% | -33.5% | -$4M | — | $31M |
| Jun '21 | $11M | -$4M | 67.1% | -36.0% | -$5M | — | $35M |
How the market has priced APYX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Apyx Medical Corp's revenue has grown 13.8% per year. These are computed facts, not advice.
As of FY2025, Apyx Medical Corp reported $38M of total debt against $32M of cash; operating income covered interest expense -1.2×.
In FY2025, gross margin was 62.5%, operating margin -12.2%, and net margin -21.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.